NCT05005429 2025-12-23
BIMES
Fundación GECP
Phase 2 Completed
Clinical Trials
13 trialsNCT04396535 2025-11-17
Docetaxel With or Without Bintrafusp Alfa for the Treatment of Advanced Non-small Cell Lung Cancer
Mayo Clinic
Phase 2 Terminated
NCT04874311 2025-08-13
TRUST
Institut Bergonié
Phase 2 Recruiting
NCT04396886 2024-05-09
Bintrafusp Alfa in Previously Treated Patients With R/M Non-keratinizing NPC
The University of Hong Kong
Phase 2 Completed
NCT05445882 2024-04-02
N-803 Alone or in Combination With BN-Brachyury Vaccine or Bintrafusp Alfa (M7824) for Participants With Castration Resistant Prostate Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Withdrawn
NCT03833661 2023-10-25
M7824 Monotherapy in Locally Advanced or Metastatic Second Line (2L) Biliary Tract Cancer (Cholangiocarcinoma and Gallbladder Cancer)
EMD Serono
Phase 2 Completed
NCT04246489 2023-10-23
Bintrafusp Alfa Monotherapy in Platinum-Experienced Cervical Cancer
EMD Serono
Phase 2 Completed
NCT04971187 2023-08-01
Bintrafusp Alfa With Chemotherapy for Tyrosine Kinase Inhibitor-Resistant EGFR-Mutant Non-small Cell Lung Cancer
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT04489940 2023-04-10
Bintrafusp Alfa in High Mobility Group AT-Hook 2 (HMGA2) Expressing Triple Negative Breast Cancer
EMD Serono
Phase 2 Terminated
NCT04560686 2022-07-28
Bintrafusp Alfa Before Surgery for the Treatment of Untreated Resectable Non-small Cell Lung Cancer
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT04727541 2022-05-23
NEOBIL
AIO-Studien-gGmbH
Phase 2 Terminated
NCT04428047 2022-04-06
ICING
UNICANCER
Phase 2 Terminated
NCT04878250 2021-05-07
PEBBLE
Queen Mary University of London
Phase 2 Unknown